Format

Send to

Choose Destination
Curr Opin Pharmacol. 2017 Dec;37:112-117. doi: 10.1016/j.coph.2017.10.013. Epub 2017 Nov 10.

Pharmacological management of gastroesophageal reflux disease in infants: current opinions.

Author information

1
Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, USA.
2
College of Pharmacy, Helwan University, Cairo, Egypt.
3
Divisions of Neonatology and Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA. Electronic address: Sudarshan.Jadcherla@nationwidechildrens.org.

Abstract

Gastroesophageal reflux disease (GERD) constitutes a troublesome symptom complex resulting from retrograde passage of gastric contents into the esophagus or extra-esophageal regions. Premature-born, high-risk infants and those with neuro-aero-digestive pathologies are at increased risk. Critical review over the last 3 years was conducted, and current opinions on pharmacological targets include agents aimed at prevention of transient lower esophageal sphincter relaxation, modification of the physico-chemical composition of gastric contents, modification of gut motility, or altering sensory thresholds to ameliorate the troublesome symptoms. As data from well-designed studies is limited in the infant population, information from adult studies has been cited where potential application may be helpful.

PMID:
29128854
DOI:
10.1016/j.coph.2017.10.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center